Utah People's Post

The Latest News from the Beehive State

Saturday, June 25, 2022
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / Nivolumab is the New Weapon Against Cancer

Nivolumab is the New Weapon Against Cancer

December 7, 2014 Posted by Contributor

Nivolumab is the new weapon against cancer

After conducting serveral clinical trials on patients with Hodgkin’s Lymphoma, researchers believe that nivolumab is the new weapon against cancer.

Experts report a breakthrough regarding Hodgkin’s Lymphoma after conducting a clinical trial on patients with resistant forms of the disease. This new compound used in the clinical trial, allows the immune system to efficiently recognize and destroy cancer cells and showed great promise in 87 percent of the patients. Reports show that the patients’ tumors were in complete or partial remission after participating in this clinical trial.

The results of this trial present the most important evidence to date of the potential treatments that can increase the capability of the immune system to attack and successfully kill cancer cells. Clinical trials conducted by using these immunotherapy techniques in other types of cancer have made them very effective in some groups of patients, this new study is different because almost all patients received the same treatement.

The new drug, nivolumab, that was used in this clinical trial has been approved by the U.S Food and Drug Administration (FDA) and is considered to be a revolutionary drug for treating Hodgkin’s Lymphoma. Experts say that another phase of the trial in under way, this time on a multinational scale.

The study’s co-author Margaret Shipp said that the aspect which made the results encouraging was the fact that progress has been made regarding patients who went through every treatement possible before participating in this trial. Also, she was pleased to see that the drug was so efficient that patients were still doing well despite the fact that more than a year had passed since the treatment was administered.

The study led by Margaret Shipp and Philippe Armand was conducted on 23 patients with resistant forms of Hodgkin’s Lymphoma. This disease attack white blood cells called lymphocytes and bone marrow.  Even though it is fairly uncommon, with less than 10.000 cases each year in the United States, it is one of the most common form of cancers in children and teenagers.  In this study, almost 80 percent of the patients already had stem cell transplants, but more than a third eventually relapsed.

The patients in the clinical trial received intravenous nivolumab twice a week, which is an antibody that blocks a protein called PD-1 found on the surface of immune system T cells. These T cells are the human’s body main defense line, they identify diseased cells and attacks those cells. The PD-1 protein, the malicious protein, binds to other proteins such as PD-L1 and PD-L2 that can be found on the surface of cancer cells and paralyzes the T cells leaving our body defenseless. What nivolumab basically does is to block the PD-1 protein allowing the T cells to continue the attack on the cancer cells.

Six months after researchers have tested this new drug, twenty out of 23 patients showed great promise regarding the size of the tumors which shrank exponentially. Four of the patients were even cancer free after the administration of nivolumab.  Most of the patients continue to show progress after one year of treatment.

Side effects of the drug were observed in patients with solid tumors, more than 20 patients showed serious adverse effect to the treatment but fortunately none of these effects were life-threatening.

Experts say that the reason nivolumab had such a high response rate in the study is the fact that HL consists in a small number of tumor cells and the T cells from our immune system is very effective against such a small number of tumors. All researchers had to was to find a way to activate the T cells found in the body’s immune system and trust those cells to do their work.

Share this:

  • Tweet
  • Share on Tumblr
  • Email

Filed Under: Health Tagged With: experimental drug used to fight Hodgkin's Lymphoma, FDA approved drug to be used in clinical trials, FDA approves nivolumab in cancer clinical trials, New drug against cancer, Nivolumab drug fights cancer

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

June 29, 2018 By Amelia Donovan

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

June 29, 2018 By Amelia Donovan

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

June 28, 2018 By Amelia Donovan

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

June 27, 2018 By Amelia Donovan

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

June 27, 2018 By Amelia Donovan

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

June 26, 2018 By Amelia Donovan

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

June 25, 2018 By Amelia Donovan

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

June 23, 2018 By Amelia Donovan

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

June 22, 2018 By Amelia Donovan

456 People Dead at U.K. Hospital after Taking too Many Painkillers

June 21, 2018 By Amelia Donovan

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

June 20, 2018 By Amelia Donovan

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

    Jun 29, 2018
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

    Jun 29, 2018
  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

    Jun 27, 2018
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

    Jun 25, 2018
  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

    Jun 22, 2018
  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

    Jun 21, 2018
  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

    Jun 19, 2018
  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

    Jun 18, 2018
  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

    Jun 15, 2018
  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

    Jun 13, 2018

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2022 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact